Kisunla



Treatment Location:	
Treatment Location.	

PROVIDERS: Please include the following to expedite the order:

Patient Demographics; Insurance Information; All Clinical Documentation Supporting the Diagnosis Including any Previous or Current Therapies, Pertinent Labs, or Diagnostic Testing (Cognitive Screening, Amyloid Beta Pathology on Pet/LP, Recent Brain MRI); Most Recent Office Visit Note, CMS Registry Number, Clinical Trial Number

Patient Phone: DOB:
31.84 ICD Description:
Weight (lbs/kg): Height:
Last Treatment Date: Next Due Date:
Referral Coordinator Email:
Provider NPI:
Phone: Fax:
City: State: Zip:
LABORATORY ORDERS
□ CBC □ at each dose □ every □ CMP □ at each dose □ every □ Other: □ Frequency: □ Please check this box if you DO NOT authorize Infusion for Health to order and draw labs indicated for clinical clearar and/or insurance authorization prior to treatment. THERAPY ADMINISTRATION Kisunla Intravenous Infusion
Dose: ☐ Initial Doses (please indicate if patient has received any initial doses): ☐ Infusion 1: 350 mg ☐ Infusion 2: 700 mg ☐ Infusion 3: 1050 mg ☐ Week 4 and Beyond: 1400 mg ☐ Week 4 and Beyond: 1400 mg ☐ Frequency: Every 4 weeks ☐ Refills: ☐ Zero / ☐ for 12 months / ☐ ☐ (if not indicated, order will expire one year from date sign to ensure that a brand name product is dispensed, the prescriber must handwrite "Brand Medically Necessary" on the prescription form. If not indicated, 14H is authorized to administer a generic or biosimilar.
t

Please check this box if you DO NOT authorize Infusion for Health to complete a Peer-to-Peer on behalf of the prescribing provider for an insurance company that denies authorization for treatment.